Robert S. Epstein, M.D., has served on Veracyte’s board of directors since 2015, including as Chairman since 2023.

From 2010 to 2012, Dr. Epstein served as President of the Medco-UBC Division and as Chief Research and Development Officer of Medco Health Solutions, Inc., a managed healthcare company.

Prior to that, Dr. Epstein served as Medco’s Chief Medical Officer from 1997 to 2010.

He is a member of the board of directors of Fate Therapeutics, Inc. and Illumina, Inc. and previously served as a member of the board of directors of Aveo Pharmaceuticals, Inc. and of Decipher Biosciences, where he was Chairman.

Dr. Epstein is the former President of the International Society of Pharmacoeconomics and Outcomes Research, and served on the board of directors of the Drug Information Association and the International Society of Quality of Life.

He has also served on the Centers for Disease Control and Prevention’s Evaluation of Genomic Applications in Practice & Prevention Stakeholder Committee and the Agency for Healthcare Research and Quality Centers for Education and Research on Therapeutics Committee.

Dr. Epstein holds a B.S. in Biomedical Science and an M.D. from the University of Michigan and an M.S. in Preventive Medicine from the University of Maryland.

Eliav Barr, M.D., joined the Veracyte board of directors in August 2022.

Dr. Barr built his distinguished career at Merck Research Laboratories (MRL), a division of Merck & Co., Inc., where he has served as Head of Global Clinical Development and Chief Medical Officer since 2022. In this role, he oversees development programs for pipeline and in-line products in the Cardiovascular, Diabetes/Endocrine/ Metabolism, Immunology, Neurology, Oncology, Psychiatry, Respiratory, and Vaccines/Infectious Diseases therapeutic areas.

He is also the Chairperson of the Late Development Review Committee for MRL’s pipeline products. Dr. Barr has held numerous leadership positions within MRL since joining the company in 1995, including serving as Senior Vice President, Global Medical and Scientific Affairs from 2018 to 2022.

He previously served as Senior Vice President, Infectious Diseases and Vaccines from 2016 to 2018. Notably, he led the development of Merck’s human papillomavirus (HPV) vaccines, which have become key tools in the global effort to reduce the burden of certain cancers and diseases caused by HPV.

Dr. Barr holds a B.S. from Pennsylvania State University and an M.D. from Jefferson Medical College of Thomas Jefferson University and completed an Internal Medicine residency and Cardiology Fellowship at Johns Hopkins.

Muna Bhanji joined the Veracyte board of directors in 2021. Ms. Bhanji has more than 30 years of strategic and operational experience in the biopharmaceutical industry.

She is the Founder and President of Tiba Global Access LLC, an independent senior advisory/consultancy focused on commercialization and market access strategy development, serving the biopharmaceutical industry.

She built her career at Merck & Company, Inc., serving most recently as Senior Vice President of Global Market Access & Policy, Global Human Health. In that role, she developed pharmaceutical access and affordability strategies in a highly regulated environment, driving access to medicines in the United States and globally.

Ms. Bhanji serves on the boards of biopharmaceutical companies Ardelyx, Intellia, and Cytokinetics, Inc., as well as the nonprofit organization Corus International. She previously served on the board of Possible Health, a non-profit with ties to Nepal that delivers affordable and high-quality care to rural and underserved communities, and on the Foundation of Managed Care Pharmacy, which is the research, educational, and philanthropic arm of the Academy of Managed Care Pharmacy. Ms. Bhanji earned her B.S. in Pharmacy from Rutgers University and an M.B.A. from St. Joseph’s University.

Karin Eastham has served as a member of the Veracyte board of directors since 2012. Ms. Eastham is a veteran life sciences industry executive and leader.

From 2004 to 2008, she served as Executive Vice President and Chief Operating Officer, and as a member of the board of trustees, of the Burnham Institute for Medical Research, a non-profit corporation engaged in biomedical research.

From 1999 to 2004, she was Senior Vice President, Chief Financial Officer and Secretary of Diversa Corporation, a biotechnology company.

She previously held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Corporation, a diagnostics company, from 1976 to 1988.

Ms. Eastham currently serves on the board of directors of Personalis, Inc. and has previously served on the boards of Nektar Therapeutics, Geron Corporation, MorphoSys AG, Amylin Pharmaceuticals, Inc., Genoptix, Inc., Tercica, Inc., Trius Therapeutics, Inc. and Illumina, Inc. Ms. Eastham received a B.S. in Accounting and an M.B.A. from Indiana University and is a Certified Public Accountant.

Jens Holstein has served on the Veracyte board of directors since August 2020. Mr. Holstein has over 25 years of financial and management expertise, spanning an array of global life science businesses. He currently serves as Chief Financial Officer of BioNTech SE, an immunotherapy biopharmaceutical company based in Mainz, Germany.

Previously, Mr. Holstein was the Chief Financial Officer of MorphoSys, a clinical-stage biopharmaceutical company based in Munich, Germany, from 2011 to 2020.

Before joining MorphoSys, he worked at the pharmaceutical company Fresenius Kabi AG, a subsidiary of Fresenius SE, as Regional Chief Financial Officer for the Europe/Middle East Region and as Managing Director of Fresenius Kabi Deutschland GmbH. From 2006 to 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong.

Previous to this appointment, Mr. Holstein held multiple other leadership positions within the Fresenius SE Group.

Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry.

He has previously served as a director of InflaRx N.V., a biopharmaceutical company.

He holds a Diploma in Business Administration from the University of Münster (Germany).

Evan Jones began serving as a member of the Veracyte board of directors in 2008. Mr. Jones has achieved a distinguished career leading and investing in pioneering life sciences companies.

He has served as Managing Member of jVen Capital, LLC, a life sciences investment company, since 2007.

He previously served as Chief Executive Officer of OpGen Inc., a publicly held genetic analysis company, from 2013 to March 2020, and as a director from 2009 to 2020.

Mr. Jones co-founded Digene Corporation, a publicly traded molecular diagnostics company focused on women’s health, serving as Chairman of the Board from 1995 until its acquisition in 2007 and as Chief Executive Officer from 1990 to 2006.

He is a member of the board of directors for Protagene GmbH, a leading provider of analytical services for biologicals and cell and gene therapy development. He previously served as a member of the board of directors of Foundation Medicine, Inc., Fluidigm Corporation and CAS Medical Systems, Inc. Mr. Jones received a B.A. in Biotechnology from the University of Colorado and an M.B.A. from The Wharton School at the University of Pennsylvania.

Tom Miller, Ph.D., joined the Veracyte board of directors in September 2024. Dr. Miller is a scientist and entrepreneur with a focus on the nexus of AI, chemistry, and biology.

Since 2020, he has served as Co-founder and Chief Executive Officer of Iambic Therapeutics, a clinical-stage biotechnology company that is disrupting the therapeutics landscape with a unique, AI-driven, drug-discovery platform.

Prior to this, he served over 10 years as a professor at the California Institute of Technology (Caltech), receiving tenure, publishing over 140 peer-reviewed articles and patents and receiving numerous awards for research and entrepreneurial excellence.

Dr. Miller earned a B.S. in Chemistry and Mathematics from Texas A&M University and a Ph.D. in Theoretical Chemistry from the University of Oxford. 

Brent Shafer joined the Veracyte board of directors in September 2024. Mr. Shafer is a veteran healthcare industry leader with over 40 years of experience in health information technology, medical devices, and other related industries.

From 2018 to 2021, he was Chairman and Chief Executive Officer of Cerner Corporation, which was acquired by Oracle Corporation.

Prior to that, Mr. Shafer held key roles at Royal Philips, the health technology company, including as Chief Executive Officer of Philips North America and of the Philips Home Healthcare Solutions business.

Before joining Philips, Mr. Shafer was Vice President and General Manager of Hillrom’s Patient Care Environment Division and worked at GE Medical Systems in key sales, marketing, and general management positions.

Following early roles at Intermountain Healthcare’s Primary Children’s Hospital and Johnson & Johnson, Mr. Shafer held senior roles at Hewlett-Packard’s Medical Products Group.

He currently serves on the boards of Baxter International Inc. and Tactile Systems Technology, Inc. Mr. Shafer holds a B.S. in Communications from the University of Utah. 

Marc Stapley joined Veracyte in 2021 as Chief Executive Officer and a member of the company’s board of directors. Mr. Stapley has deep experience in the genomic diagnostics industry, including significant expertise building and leading complex global enterprises.  


Prior to Veracyte, he served as Chairman and Chief Executive Officer of Helix, a leading population genomics company, from 2019 to 2021. Under Mr. Stapley’s leadership, Helix built one of the largest COVID-19 testing labs in the United States and became a national leader in viral surveillance.  


Prior to Helix, Mr. Stapley served in key executive leadership positions at Illumina from 2012 to 2019, including as Chief Financial Officer, Chief Administrative Officer and Executive Vice President, where he led many functions including G&A, corporate strategy, business development, population genomics, and government affairs.  


Prior to Illumina, Mr. Stapley was Senior Vice President, Finance, at Pfizer Inc. and before that, he served in a variety of senior finance roles at Alcatel-Lucent, Cadence Design Systems, Inc., and Coopers & Lybrand (now PwC).  


He currently serves as a member of the board of directors of Helix and Glaukos. Mr. Stapley holds a B.Sc. (Honors) in Mathematics from the University of Reading (England). 

Rebecca Chambers joined Veracyte as Chief Financial Officer in 2021. Ms. Chambers has extensive healthcare leadership experience, previously serving as Chief Financial Officer for Outset Medical, a publicly traded medical technology company focused on reducing dialysis cost and complexity.

Prior to Outset Medical, she served in several financial leadership roles at Illumina, including Vice President of Financial Planning and Analysis and Vice President of Investor Relations and Treasury.

She has also served as Head of Investor Relations and Corporate Communications at Myriad Genetics.

Earlier in her career, Ms. Chambers held various roles in investor relations at Life Technologies (now part of Thermo Fisher Scientific), served as a Vice President at Bank of America and as a Senior Research Associate at Millennium Pharmaceuticals (now part of Takeda Pharmaceuticals).

She holds a B.S. in Biology from John Carroll University and an M.B.A. from the S.C. Johnson Graduate School of Management at Cornell University.